
|Videos|August 13, 2011
Dr. O'Shaughnessy on Continued Access to Avastin
Author(s)Joyce A. O'Shaughnessy, MD
Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on Continued Access to Avastin
Advertisement
Joyce A. O'Shaughnessy, MD, Breast Cancer Research, Baylor Sammons Cancer Center in Dallas, TX, describes that all she truly needs is access to Avastin (bevacizumab) as a treatment option for breast cancer. She believes that with its many other approvals, both in the US and in the Europe, it will continue to be accessible with a large amount of information available on its use. Having tools, such as Avastin, readily available that are non-cross resistant with chemotherapy is necessary for patients with very few options left.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
2
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
3
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
4
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
5



































